Literature DB >> 10986219

Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.

C J Rees1, K Oppong, H Al Mardini, M Hudson, C O Record.   

Abstract

BACKGROUND AND AIM: An oral glutamine load in cirrhotic patients awaiting liver transplantation was shown to cause a rise in blood ammonia and psychometric abnormalities which were reversed by hepatic transplantation. L-Ornithine-L-aspartate (LOLA) has been shown to reduce ammonia and improve psychometric function in patients with hepatic encephalopathy. The aim of the present study was to assess the effect of LOLA in healthy patients with cirrhosis and no evidence of clinical encephalopathy after challenging the central nervous system by administration of oral glutamine. PATIENTS AND METHODS: Eight cirrhotics (Child's B or C) without transjugular intrahepatic portosystemic shunts (TIPS) and seven with TIPS underwent two oral glutamine (20 g) challenges, receiving LOLA (5 g intravenously) on one occasion and placebo on the other in random order. Psychometric tests, including choice reaction time (CRT) and number connection test, were performed before and after glutamine, together with electroencephalography and blood ammonia.
RESULTS: Mean basal ammonia was 27 (SEM 5) micromol/l in non-TIPS and 76 (10) micromol/l in TIPS patients (p<0.05). Basal CRT 2 was 0.643 (0.033) s in non-TIPS and 0.825 (0.076) s in TIPS patients (p<0.02). In non-TIPS patients, ammonia increased to 36 (10) micromol/l when LOLA was administered and to 62 (13) micromol/l with placebo (p<0.02). There was no alteration in psychometric function in non-TIPS patients after glutamine when LOLA was given but when placebo was given, glutamine caused prolongation of CRT (p=0.02). Glutamine did not affect psychometric function in TIPS patients with or without LOLA.
CONCLUSION: This study showed that LOLA ameliorated the deleterious psychometric effects of glutamine in Child's grade B and C patients with cirrhosis without TIPS and supports its use in clinical practice in hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986219      PMCID: PMC1728090          DOI: 10.1136/gut.47.4.571

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  A rapid method for blood ammonia determination using the new blood ammonia checker (BAC) II.

Authors:  J R Huizenga; A Tangerman; C H Gips
Journal:  Clin Chim Acta       Date:  1992-09-15       Impact factor: 3.786

Review 2.  Neurochemistry of hepatic encephalopathy.

Authors:  C O Record
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

3.  [Influence of ornithine aspartate on the experimentally induced hyperammoniemia. Clinico-experimental study].

Authors:  D Henglein-Ottermann
Journal:  Ther Ggw       Date:  1976-09

4.  Oral glutamine challenge in cirrhotics pre- and post-liver transplantation: a psychometric and analyzed EEG study.

Authors:  K N Oppong; H Al-Mardini; M Thick; C O Record
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

Review 5.  Therapeutic modalities in portal hypertension.

Authors:  C J Rees; M Hudson; C O Record
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-01       Impact factor: 2.566

6.  Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.

Authors:  G Kircheis; R Nilius; C Held; H Berndt; M Buchner; R Görtelmeyer; R Hendricks; B Krüger; B Kuklinski; H Meister; H J Otto; C Rink; W Rösch; S Stauch
Journal:  Hepatology       Date:  1997-06       Impact factor: 17.425

Review 7.  Review article: pathogenesis and treatment of chronic hepatic encephalopathy.

Authors:  R Jalan; J P Seery; S D Taylor-Robinson
Journal:  Aliment Pharmacol Ther       Date:  1996-10       Impact factor: 8.171

8.  Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.

Authors:  W Nolte; J Wiltfang; C Schindler; H Münke; K Unterberg; U Zumhasch; H R Figulla; G Werner; H Hartmann; G Ramadori
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

9.  Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.

Authors:  S Stauch; G Kircheis; G Adler; K Beckh; H Ditschuneit; R Görtelmeyer; R Hendricks; A Heuser; C Karoff; P Malfertheiner; D Mayer; W Rösch; J Steffens
Journal:  J Hepatol       Date:  1998-05       Impact factor: 25.083

10.  L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action.

Authors:  C Rose; A Michalak; P Pannunzio; G Therrien; G Quack; G Kircheis; R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-06       Impact factor: 3.584

View more
  14 in total

Review 1.  Hepatic encephalopathy as a complication of liver disease.

Authors:  S vom Dahl; G Kircheis; D Häussinger
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Role of ammonia and inflammation in minimal hepatic encephalopathy.

Authors:  D L Shawcross; G Wright; S W M Olde Damink; R Jalan
Journal:  Metab Brain Dis       Date:  2007-03       Impact factor: 3.584

Review 3.  The treatment of hepatic encephalopathy.

Authors:  Marsha Y Morgan; A Blei; K Grüngreiff; R Jalan; G Kircheis; G Marchesini; O Riggio; Karin Weissenborn
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

4.  Amino acid challenge in patients with cirrhosis and control subjects: ammonia, plasma amino acid and EEG changes.

Authors:  Hanan Al Mardini; Andrew Douglass; Christopher Record
Journal:  Metab Brain Dis       Date:  2006-05-04       Impact factor: 3.584

Review 5.  Assessment of minimal hepatic encephalopathy (with emphasis on computerized psychometric tests).

Authors:  Matthew R Kappus; Jasmohan S Bajaj
Journal:  Clin Liver Dis       Date:  2012-02       Impact factor: 6.126

Review 6.  Ornithine phenylacetate revisited.

Authors:  Maria Jover-Cobos; Lorette Noiret; Yalda Sharifi; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

7.  Oral tryptophan challenge studies in cirrhotic patients: no evidence of neuropsychiatric changes.

Authors:  Andrew Douglass; Hanan Al Mardini; Christopher O Record
Journal:  Metab Brain Dis       Date:  2003-09       Impact factor: 3.584

Review 8.  Pathogenesis of hepatic encephalopathy: lessons from nitrogen challenges in man.

Authors:  Hanan Mardini; Christopher Record
Journal:  Metab Brain Dis       Date:  2012-11-23       Impact factor: 3.584

Review 9.  Hepatic encephalopathy: an updated approach from pathogenesis to treatment.

Authors:  Giannakis T Toris; Christos N Bikis; Gerasimos S Tsourouflis; Stamatios E Theocharis
Journal:  Med Sci Monit       Date:  2011-02

10.  Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Roger F Butterworth; Gerald Kircheis; Norbert Hilger; Mark J W McPhail
Journal:  J Clin Exp Hepatol       Date:  2018-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.